Novartis closes tender offer for Regulus; holders get $7.00 cash plus $7.00 CVR

Regulus Therapeutics Inc.

Tender offer expired June 24 with 74.49% shares tendered; merger completed June 25.
Shareholders receive $7.00 cash per share plus a CVR that could pay $7.00 if U.S. regulatory approval for ADPKD achieved.
Regulus stock will be delisted from Nasdaq effective June 25.
All prior directors and officers removed; replaced by Novartis appointees John McKenna and Eduard Marti.
Charter and bylaws amended and restated; company becomes Novartis subsidiary.

item 2.01item 3.01item 3.03item 5.01item 5.02item 5.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.